ISIS

Isis Pharma is an innovative company in the pharmaceuticals industry. They work specifically in the developing antisense drugs meaning that Isis Pharma will first look at genes and then create drugs based on the gene information. With this strategy, Isis Pharma has been successful in discovering and developing drugs. The Isis Pharma productivity is heightened by working with many partners in the field. Another innovative idea behind Isis Pharma is that they license their drugs to these partner companies while still in development. This way, Isis Pharma can eliminate the costs of sales and marketing. Other tactics that Isis Pharma uses to ensure they are profiting while still focusing only on drug development is upfront licensing fees, paying milestones, and royalty systems. As a result of their system, Isis Pharma is a strong drug company with more than $3.5 billion in future milestone earnings.

Isis Pharma is led by Stanley T Crooke, MD, PhD, as Chairman of the Board and Chief Executive Officer. Crooke founded Isis Pharma in 1989 and has been key to developing the company’s strategy and mission. Under Crooke, Isis Pharma became the first drug company to monetize the antisense drug development approach. For his success in leading Isis Pharma, Crooke was honored by Nature Biotechnology as one of the most influential persons in the field.

Also in charge of leading Isis Pharma is B Lynne Parshall, Esq. as Director, Chief Operating Officer, and Chief Financial Officer. She joined the Isis Pharma team in 1991 and has helped with the success of legality, financing, patenting, and business aspects of the company. C. Frank Bennett, PhD. Is the Senior Vice President of Research for Isis Pharma. It is largely because of this man that Isis Pharma is the pioneer of antisense technology. Richard S. Geary, Phd is the Senior Vice President of Development for Isis Pharma. With Isis Pharma since 1995, Geary has been crucial for developing antisense drugs.